Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma
100% of patients with follicular lymphoma achieved a complete response; no occurrence of CRS above grade 1 and no ICANS of any grade
Complete responses observed in patients previously treated with CD19-targeted CAR T-cell therapy
Outpatient administration found to be feasible
WORCESTER, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ:here.
Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future.
